Medicure Inc. (CVE:MPH – Get Free Report)’s share price reached a new 52-week high on Friday. The company traded as high as C$4.40 and last traded at C$4.43, with a volume of 15,100 shares traded. The stock had previously closed at C$4.40.
Medicure Stock Performance
The firm has a market capitalization of C$44.87 million, a price-to-earnings ratio of -5.97 and a beta of 0.98. The company has a debt-to-equity ratio of 6.02, a current ratio of 0.97 and a quick ratio of 1.28. The firm has a 50 day moving average price of C$3.01 and a 200-day moving average price of C$1.62.
Medicure Company Profile
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.
Featured Stories
- Five stocks we like better than Medicure
- Starbucks Says Its Turnaround Is Done—The Numbers Make a Strong Case (With 1 Catch)
- 3 Robotics ETFs, 3 Different Ways to Bet on Humanoid Robots
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
